Physician

Paul-Moreau Bossous, M.D.

According to 2025 Medicare claims, Paul-Moreau Bossous, M.D. (NPI: 1487975439) practices nephrology in the Brownsville-Harlingen, TX market, with the plurality of this provider's patient population coming from Cameron, TX. This provider's primary affiliated billing organization is 360 KIDNEY CARE (NPI: 1104427970; TIN: 853792463) and primary practice location at 78520-9998. Bossous is affiliated with the Sound Physicians Long Term Care Management, LLC (ACO ID: A5220), participating under the MSSP model.

Bossous' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 310 traditional Medicare patients, billed 2,631 HCPCS/CPT codes, and received $288,716 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 4,089 prescription claims across 688 beneficiaries totaling $3,063,052 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 34 claims. Open Payments data shows 34 records totaling $771. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $35,695 to $288,716. Similarly, Part D prescription costs have moved sharply higher in recent years, from $2,435 to $3,063,052. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	182	786	$35,695
2017	303	3,483	$148,243
2018	294	5,065	$169,507
2019	311	3,819	$155,569
2020	267	1,133	$83,933
2021	270	1,900	$182,779
2022	346	3,007	$292,209
2023	308	2,513	$302,625
2024	310	2,631	$288,716

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	16	53	$2,435
2016	47	164	$16,285
2017	149	1,003	$103,419
2018	153	1,345	$186,747
2019	139	1,327	$224,656
2020	122	850	$147,831
2021	90	388	$33,943
2022	149	647	$330,409
2023	355	1,666	$1,223,707
2024	688	4,089	$3,063,052

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	56	309	$20,473
2018	99	905	$55,596
2019	92	870	$43,223
2020	72	764	$26,949
2021	N/R	63	$795
2022	N/R	N/R	N/R
2023	N/R	22	$350
2024	N/R	34	$491

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	44	204	$261
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	71	71	$162
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	76	79	$131
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	136	328	$93
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	139	1,754	$90

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	1,139	66,867	$1,176,496
Lokelma	Sodium Zirconium Cyclosilicate	283	17,433	$461,431
Kerendia	Finerenone	260	15,510	$315,786
Tarpeyo	Budesonide	18	540	$297,966
Velphoro	Sucroferric Oxyhydroxide	110	3,335	$248,838

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	11	$215
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	11	$151
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$125

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	34	$771	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Paul-Moreau Bossous, M.D.?

Tedicare shows public-source Medicare data for Paul-Moreau Bossous, M.D. (NPI 1487975439), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Paul-Moreau Bossous, M.D. have ACO affiliation data?

Paul-Moreau Bossous, M.D. is shown with ACO affiliation data for Sound Physicians Long Term Care Management, LLC (MSSP, ACO ID A5220).

What billing organization is linked to Paul-Moreau Bossous, M.D.?

Paul-Moreau Bossous, M.D. is linked to 360 KIDNEY CARE (billing NPI 1104427970) in the available physician profile data.

Does Paul-Moreau Bossous, M.D. have Open Payments data?

Paul-Moreau Bossous, M.D. has 34 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.